Clinical trials: Lung Cancer Non-Small Cell Cancer (NSCLC)
Solid Tumor, NSCLC
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or…
- Conditions
- Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT07873450
- Testing
- [225Ac]Ac-FL-261
- Where
- 2 sites in United States, Australia
- Volunteers
- 208 people
- Sponsor
- Full-Life Technologies UK Limited
Non-Small Cell Lung Cancer
Septum-guided Segmentectomy for 2-3 cm Clinical Stage IA3 Peripheral Non-Small Cell Lung Cancer
This is a single-center, prospective, single-arm, open-label clinical trial evaluating the efficacy and safety of septum-guided segmentectomy in patients with 2-3 cm clinical stage IA3 peripheral non-small cell lung cancer…
- Trial name
- SGS2606 (NCT07780591)
- Testing
- septum-guided anatomical segmentectomy
- Volunteers
- 100 people
- Sponsor
- Shanghai Chest Hospital
Non Small Cell Lung Cancer
A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single and multiple oral doses of TQ-A3334 and observe the efficacy of TQ-A3334 in combination with anlotinib capsules…
- Trial name
- NCT06507891
- Testing
- TQ-A3334 tablets, TQ-A3334 tablets + Anlotinib capsules
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted Therapy
The study's purpose is to understand the self-management needs of patients with NSCLC receiving targeted therapy, develop a disease self- management application (mHealth Application), and explore the effect of mHealth application…
- Trial name
- NCT05611450
- Testing
- disease self-management application
- Volunteers
- 108 people
- Sponsor
- Chang Gung Memorial Hospital
Advanced Solid Tumor
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
Evaluating the efficacy of Neratinib tablets monotherapy in treating advanced solid tumors with HER2 mutations.
- Trial name
- CVL009-C2001 (NCT06519110)
- Testing
- Neratinib tablets
- Volunteers
- 60 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Non-small Cell Lung Cancer
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
The study is evaluating the safety and tolerability of Nivolumab (BMS-936558) when combined with three platinum-based doublet chemotherapy regimens (Cisplatin/Gemcitabine; Cisplatin/Pemetrexed; and Carboplatin/Paclitaxel) in…
- Trial name
- NCT01454102
- Testing
- Nivolumab, Gemcitabine, Cisplatin
- Where
- 12 sites in United States, Canada
- Volunteers
- 472 people
- Sponsor
- Bristol-Myers Squibb
Squamous Non Small Cell Lung Cancer
AZD2014 and Weekly Paclitaxel in Squamous NSCLC
Open--label, phase 2a, multi-centre, single-arm study to assess the efficacy and safety of AZD2014 and weekly paclitaxel in patients with squamous non-small cell lung cancer (NSCLC)
- Trial name
- NCT02403895
- Testing
- Open-label AZD2014, paclitaxel
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
NSCLC, Neutropenia
A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy.
- Conditions
- NSCLC, Neutropenia, Febrile Neutropenia
- Trial name
- NCT01560195
- Testing
- Pegylated rhG-CSF: 100µg/kg, Pegylated rhG-CSF: 6mg
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non Small Cell Lung Cancer, Small Cell Lung Cancer
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
Hypothesis 1- Using IMRT, the radiation therapy (RT) dose can be safely escalated from 58 Gy to 74 Gy given as 6 fractions/week with concurrent chemotherapy.
- Conditions
- Non Small Cell Lung Cancer, Small Cell Lung Cancer, Thymoma, Thymus Neoplasms
- Trial name
- ESIMRT (NCT00921739)
- Testing
- Esophageal sparing IMRT
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)
The primary goal of the study is to evaluate an investigational drug's effectiveness as a treatment for Non small-cell lung cancer (NSCLC)
- Trial name
- NCT00034957
- Testing
- Investigational drug
- Where
- 12 sites in United States
- Sponsor
- Pfizer
Chemotherapeutic Agent Toxicity, Lung Cancer
Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to find the highest tolerable dose of Anvirzel (Nerium Oleander) that can be given to lung cancer patients receiving standard therapy with carboplatin and docetaxel.
- Trial name
- NCT01562301
- Testing
- Carboplatin, Docetaxel, Anvirzel
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer Stage III
A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
This is a prospective, single arm, phase II study to evaluate the efficacy and safety of Envafolimab in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not progressed after prior…
- Trial name
- NCT05414630
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Cancer Hospital
Breast Cancer, Lung Cancer (Non-Small Cell)
Effectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficacy of Chemotherapy in Adults With Breast, Lung and Colon Cancer
This clinical study evaluates whether a supervised, multimodal therapeutic exercise program started before chemotherapy and continued during treatment can improve treatment outcomes in patients aged 35 to 65 years with breast…
- Conditions
- Breast Cancer, Lung Cancer (Non-Small Cell), Colorectal Cancer, Physical Activity
- Trial name
- PREDU (NCT07502963)
- Testing
- PREDU Exercise Program, Recommendation Exercise Program
- Where
- 3 sites in Spain
- Volunteers
- 70 people
- Sponsor
- University of Vic - Central University of Catalonia
Non Small Cell Lung Cancer
A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer
This is a randomized clinical trial of Paclitaxel (Genexol®) and Cisplatin versus Paclitaxel loaded polymeric micelle (Genexol-PM®) and Cisplatin in advanced non small cell lung cancer.
- Trial name
- NCT01023347
- Testing
- Paclitaxel (Genexol®), Paclitaxel loaded polymeric micelle (Genexol-PM®)
- Where
- South Korea
- Volunteers
- 276 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Stage IV Non-small Cell Lung Cancer
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in patients with stage IV non-squamous…
- Trial name
- NCT03559049
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
ITIL-168 in Advanced Solid Tumors
DELTA-2 is a phase 1 clinical trial to evaluate the safety, feasibility, and preliminary efficacy of ITIL-168 with pembrolizumab in participants with advanced cancer whose disease has progressed after standard therapy.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- DELTA-2 (NCT05393635)
- Testing
- ITIL-168
- Sponsor
- Instil Bio
Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
This phase Ib/II trial studies the best dose of carboplatin when given together with berzosertib, gemcitabine and pembrolizumab and to see how well it works in treating patients with stage IV squamous cell non-small cell lung…
- Trial name
- NCT04216316
- Testing
- Berzosertib, Biospecimen Collection, Carboplatin
- Where
- 34 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC Stage II, NSCLC, Stage IIIA
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
This study examines preoperative Erlotinib in patients with operable stage II and IIIA Non-small-cell lung cancer (NSCLC) harboring EGFR mutations.
- Trial name
- NCT01470716
- Testing
- Erlotinib
- Where
- South Korea
- Volunteers
- 26 people
- Sponsor
- National Cancer Center, Korea
Non-small Cell Lung Cancer
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
This study evaluated the efficacy and safety of gumarontinib combined with third-generation EGFR-TKI in the treatment of locally advanced or metastatic NSCLC with MET amplification after first-line EGFR-TKI failure, without…
- Trial name
- NCT06452433
- Testing
- gumarontinib, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
- Volunteers
- 91 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Circulating Tumor Cell, Lung Cancer
Sequence of Vessel Interruption and Circulating Tumor Cells in Surgical Lung Cancer
This study aims to define the impact of the sequence of vessel interruption on change in CTC and CTC clusters density in the tumor-draining pulmonary vein between the period before surgical manipulation and before tumor-draining…
- Conditions
- Circulating Tumor Cell, Lung Cancer, Surgery
- Trial name
- CTC-01 (NCT03645252)
- Testing
- Vein interruption before any other surgical manipulation, Arteries interruption before vein interruption
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Laval University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.